Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma

StatusCompleted
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Completed
    • Enrollment target: estimated 600 to confirmed 573
    • Primary and study completion dates changed from estimate of Dec 2025 to Nov 18, 2024
    • Site details revised
    v25
  2. Enrollment target: 300 to 600v24
  3. 2 versions Re-verified since Jan 25, 2023, no change to tracked fieldsv22-v23
  4. Primary completion date: Dec 2021 to Dec 2025v21
  5. Primary completion date: Dec 2020 to Dec 2021
    • Primary endpoint revised
    • Eligibility criteria expanded, about 2 words
    v20
Show 18 earlier versionsHide 18 earlier versions
  1. Re-verified, no change to tracked fieldsv19
  2. Study Status, Eligibilityv18
  3. 2 versions Re-verified since Apr 21, 2016, no change to tracked fieldsv16-v17
  4. Primary completion date: Dec 2014 to Dec 2020
    • Study completion date: Dec 2018 to Dec 2025
    v15
  5. Study Status, Study Description, Outcome Measuresv14
  6. Re-verified, no change to tracked fieldsv13
  7. Primary completion date: Dec 2012 to Dec 2014
    • Study completion date: Dec 2014 to Dec 2018
    v12
  8. 4 versions Re-verified since Jun 14, 2010, no change to tracked fieldsv8-v11
  9. Primary completion date: Dec 2012
    • Study completion date: Dec 2014
    • Eligibility criteria revised
    v7
  10. Eligibility criteria revisedv6
  11. Eligibility criteria shortened, about 1 wordv5
  12. Study site revised
    • Eligibility criteria shortened, about 1 word
    v4
  13. 2 versions Re-verified since Feb 8, 2007, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Stanford University
635 trials monitored
See 42 trials at risk
Liver Cancer
1,606 trials monitored
See 69 trials at risk
The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)
Trial Details
NCT Number NCT00373347
Lead Sponsor Stanford University
Conditions
(from sponsor)		 Liver Cancer
Related terms Liver Neoplasms
Enrollment 573 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov